CEO, Systemic Therapeutics Corp
UBC
Toronto, Ontario, Canada
Fady Hannah-Shmouni, MD FRCPC is a physician-scientist specializing in neuroendocrinology/genetics, and an advisor/investor in early-stage medtech, biotech, and blockchain companies. He completed clinical training in internal medicine at Yale School of Medicine; adult endocrinology, diabetes and metabolism at the National Institutes of Health, America’s research hospital; and clinical biochemical genetics at the University of Toronto. He is board-certified in internal medicine and endocrinology by the American Board of Internal Medicine and Royal College of Physician and Surgeons of Canada; and in clinical hypertension by the American Society of Hypertension.
Dr Shmouni is a staff physician at Vancouver General Hospital (UBC), and Trillium Health Partners (UofT), practicing endocrinology and internal medicine. He is a fellow with the Royal College of Physicians and Surgeons of Canada and an active committee member of the Endocrine Society, International Society of Hypertension, Hypertension Canada Clinical Practice Guidelines, and is the Vice Chair of the Pituitary, Gonad, Adrenal and Neuroendocrine Resource Center of the American Association of Clinical Endocrinology. He is the Editor-In-Chief of Endocrine and Metabolic Science (Elsevier), and has authored/co-authored over 100 original articles, reviews and book chapters on neuroendocrine, genetic and metabolic conditions.
Dr Shmouni is the Co-Founder and Chief Executive Officer of Systemic Therapeutics Corp (systemicTx.com), a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies for metabolic disorders focusing on the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP), based on first-in-class small molecule SREBP inhibitors. The Company aims to provide new treatment options for dyslipidemia, diabetes and fatty liver. He co-founded FalconView Venture Capital and Tigris Digital, specializing in early-stage startup consultations and investments. He is an investor and board advisor for Exerkine (exerkine.com), a biotechnology company developing novel therapies for the treatment of genetic and aging-associated diseases, and Ovenue (ovenue.com), industry's first open decentralised finance protocol that allows monetization and financing of any asset through their unique digital asset marketplace; he hopes to unlock healthcare assets through this process, where companies will be able to buy, sell, raise capital, issue royalties, and borrow against their most undervalued asset portfolio.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Thursday, May 12, 2022
1:30 PM – 2:45 PM